Open AccessThis article is
- freely available
Targeting Plasmodium falciparum Hsp90: Towards Reversing Antimalarial Resistance
Department of Laboratory Medicine & Pathobiology, University of Toronto, Canada
Department of Pathology & Laboratory Medicine, The University of Calgary, Calgary, AB, Canada
Department of Microbiology, Immunology, and Infectious Diseases, The University of Calgary, Diagnostic & Scientific Centre, Room 1W-416, 9-3535 Research Road NW, Calgary, AB T2L 2K8, Canada
* Author to whom correspondence should be addressed.
Received: 8 December 2012; in revised form: 18 January 2013 / Accepted: 23 January 2013 / Published: 4 February 2013
Abstract: Malaria continues to exact a great human toll in tropical settings. Antimalarial resistance is rife and the parasite inexorably develops mechanisms to outwit our best drugs, including the now first-line choice, artesunate. Novel strategies to circumvent resistance are needed. Here we detail drug development focusing on heat shock protein 90 and its central role as a chaperone. A growing body of evidence supports the role for Hsp90 inhibitors as adjunctive drugs able to restore susceptibility to traditionally efficacious compounds like chloroquine.
Keywords: malaria; hsp90; antimalarial resistance
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Shahinas, D.; Folefoc, A.; Pillai, D.R. Targeting Plasmodium falciparum Hsp90: Towards Reversing Antimalarial Resistance. Pathogens 2013, 2, 33-54.
Shahinas D, Folefoc A, Pillai DR. Targeting Plasmodium falciparum Hsp90: Towards Reversing Antimalarial Resistance. Pathogens. 2013; 2(1):33-54.
Shahinas, Dea; Folefoc, Asongna; Pillai, Dylan R. 2013. "Targeting Plasmodium falciparum Hsp90: Towards Reversing Antimalarial Resistance." Pathogens 2, no. 1: 33-54.